Attached files

file filename
10-Q - FORM 10-Q - KALOBIOS PHARMACEUTICALS INCd401713d10q.htm
EX-4.2 - SPECIMEN OF STOCK CERTIFICATE - KALOBIOS PHARMACEUTICALS INCd401713dex42.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - KALOBIOS PHARMACEUTICALS INCd401713dex312.htm
EX-32.2 - CERTIFICATION BY THE CHIEF FINANCIAL OFFICER - KALOBIOS PHARMACEUTICALS INCd401713dex322.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - KALOBIOS PHARMACEUTICALS INCd401713dex311.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Kalobios Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David C. Pritchard, the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

September 24, 2012    

/s/ David C. Pritchard

   

David C. Pritchard

President and Chief Executive Officer

    (Principal Executive Officer)

A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), has been provided to KaloBios Pharmaceuticals, Inc. and will be retained by KaloBios Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of KaloBios Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.